Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer
- 14 November 2005
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 118 (8) , 2013-2019
- https://doi.org/10.1002/ijc.21576
Abstract
Immunocytochemical (ICC) detection of disseminated tumor cells (DTC) in bone marrow (BM) in early breast cancer is an independent prognostic factor. The significance of circulating tumor cells (CTC) in peripheral blood (PB) needs further exploration and comparison to DTC detection. PB and BM were prospectively collected from 341 breast cancer patients median 40 months after operation. PB samples were analyzed for tumor cells by a negative immunomagnetic technique (10 × 106 cells/test). BM aspirates were analyzed by standard ICC (2 × 106 cells/test). CTC were present in 10% of the patients and DTC in 14%. Thirty‐seven relapses and 14 breast cancer deaths have occurred at median 66 months after diagnosis. Both CTC‐status and DTC‐status were significantly associated with disease free survival (DFS) (event rate: CTC‐positive 26.5% vs. CTC‐negative 9.1%; DTC‐positive 29.2% vs. DTC‐negative 7.8%) (p < 0.001/p < 0.001, log rank) and breast cancer specific survival (event rate: CTC‐positive 17.6% vs. CTC‐negative 2.6%; DTC‐positive 12.5% vs. DTC‐negative 2.7%) (p < 0.001/p < 0.001). The presence of both CTC and DTC (n = 8) resulted in an especially poor prognosis (p < 0.001). In node negative patients, DTC‐status, but not CTC‐status, predicted differences in DFS (p = 0.006 vs. p = 0.503). Excluding 23 patients with breast cancer‐related events prior to the sample collections, CTC detection was not significantly associated with DFS/distant‐DFS (p = 0.158/0.193), in contrast to DTC detection (p < 0.001/p = 0.516). Applied to early stage disease, CTC analysis of increased volumes of PB appears less sensitive and prognostic than standard DTC analysis. Currently, this does not support an exchange of BM with PB for analysis of occult tumor cells.Keywords
Funding Information
- The Norwegian Cancer Society, The Norwegian Foundation of Health and Rehabilitation
This publication has 30 references indexed in Scilit:
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer PatientsClinical Cancer Research, 2004
- Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast CancerJournal of Clinical Oncology, 2003
- Molecular Detection of Cytokeratin-19–Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic SignificanceJournal of Clinical Oncology, 2002
- Epithelial Cells in Bone Marrow of Breast Cancer Patients at Time of Primary Surgery: Clinical Outcome During Long-Term Follow-UpJournal of Clinical Oncology, 2001
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000
- Micrometastatic Breast Cancer Cells in Bone Marrow at Primary Surgery: Prognostic Value in Comparison With Nodal StatusJNCI Journal of the National Cancer Institute, 1996
- Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upBritish Journal of Cancer, 1994
- Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-upEuropean Journal of Cancer and Clinical Oncology, 1991
- Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.Journal of Clinical Oncology, 1991